The broad C-suite and director buying cluster at OKYO is a positive signal of insider conviction ahead of potential pipeline catalysts. Monitor for upcoming clinical data readouts or regulatory updates that may have prompted this coordinated buying. The $101K total is modest in absolute terms but significant for a $52M market cap company with 89% analyst bullishness.
Price Chart
Executive Summary
Six OKYO Pharma insiders, including the CEO, Chief Development Officer, Chief Scientific Officer, Chief Medical Officer, and two directors, made open-market purchases totaling $101K over the past week. This cluster of insider buying at a $52M market cap company (0.19% of market cap) is a modest but notable signal of insider conviction, especially given the C-suite participation and the company's pre-revenue biotech status with an upcoming pipeline catalyst.
Key Financial Metrics
Key Facts
- Six insiders made open-market purchases totaling $101K from July 20-27, 2026.
- CEO Robert Dempsey bought $23K worth of shares at $1.54.
- Chief Medical Officer Flavio Mantelli bought $28K worth of shares at $1.40.
- Director and 10% owner Gabriele Cerrone bought $33K worth of shares at $1.45.
- Total insider buying represents approximately 0.19% of OKYO's $52M market cap.
- The cluster includes the CEO, CSO, CMO, CDO, and two directors — broad C-suite and board participation.
Financial Impact
Total insider purchases of $101K represent 0.19% of market cap — modest but meaningful for a micro-cap biotech.
Risk Factors
- Pre-revenue biotech with no approved products — binary pipeline risk.
- Insider buying at 0.19% of market cap is modest and may not indicate a near-term catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-OKYO-1786169743594 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.44 (−1.37%) |
Oct 6, 2026 20d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.44 (−1.37%) |
Sep 29, 2026 27d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.44 (+5.88%) |
Sep 8, 2026 6w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.44 (−5.88%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.44 (−8.28%) |
Jul 28, 2026 12w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.44 (−12.20%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.44 (−12.20%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers